How to Store Interferon: Stability and Handling, Per the Research

What This Page Covers, and What It Does Not

Interferons are signalling proteins (cytokines), not short synthetic peptides. That distinction matters for any storage discussion, because proteins of roughly 17–20 kDa carry folded tertiary structure that can be lost through aggregation, surface adsorption, oxidation or deamidation long before anything is visible in a vial. Short peptides tolerate some handling stresses that folded proteins do not.

This page separates two categories of information and labels every claim by category. The first category is compound-specific documentation: storage language that appears in labeling and handling documentation for interferon products. The second is general formulation science: principles that apply to lyophilized and solution-phase proteins as a class, which are frequently extrapolated to interferon but were not generated with interferon as the test article. Where this page draws on the second category, it says so in the same sentence. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision about any substance.

A Vocabulary Warning: Two Meanings of "Stability" and "Degradation"

Searching the interferon literature for "stability" or "degradation" returns a large body of work that has nothing to do with refrigerators. In molecular immunology, those words describe the turnover of proteins and nucleic acids inside living cells — how quickly a signalling molecule is ubiquitinated, routed to the proteasome, or cleared by autophagy.

Several papers illustrate the gap. Researchers reported that the CRL5–SPSB3 ubiquitin ligase targets nuclear cGAS for degradation, a mechanism describing intracellular protein turnover rather than shelf stability (PMID 38418882). A separate 2026 report described the E3 ubiquitin ligase Stub1 enhancing viral replication by promoting TBK1 degradation through chaperone-mediated autophagy (PMID 41882146), and another study described MARCH8-mediated ubiquitination regulating expression of the antiviral protein IFITM3 (PMID 41197719). None of those papers measured how a vial behaves at 2–8 °C. Readers scanning abstracts for "interferon degradation" will mostly land on this cellular literature, and it should not be read as physicochemical stability data.

Refrigeration: Lyophilized Versus Reconstituted

Lyophilized (freeze-dried) material

General lyophilized-protein formulation science holds that removing water dramatically slows the hydrolytic and deamidation reactions that dominate degradation in solution. A freeze-dried cake typically contains bulking agents and cryo/lyoprotectants (sugars such as sucrose or trehalose, sometimes albumin in older biologic formulations) whose function is to preserve the folded state during drying and subsequent storage. Because those reactions are water-dependent, lyophilized proteins as a class are generally assigned longer refrigerated shelf lives than the same protein in solution. Residual moisture content and container closure integrity are the two variables most often discussed in that general literature as determinants of how well a cake holds up.

For interferon products specifically, refrigerated storage in the standard pharmaceutical cold-chain range of 2–8 °C, with protection from light and from freezing, is the convention that appears in approved-product labeling. Labeling differs product by product — conventional interferon alfa, pegylated interferons and interferon beta formulations are not interchangeable in their storage language — so the product-specific insert, not a general rule, is the governing document for any given preparation.

Reconstituted or ready-to-use solution

Once a lyophilized protein is returned to solution, general formulation science describes a substantially shorter stability window. In aqueous phase, the dominant pathways are aggregation (monomers associating into dimers, oligomers and eventually visible particulate), adsorption to glass and plastic surfaces at low protein concentrations, oxidation of methionine and tryptophan residues, and hydrolysis. Preservative content is a major variable: multi-dose presentations containing an antimicrobial preservative are labeled differently from single-use preservative-free presentations, because the constraint in the latter case is microbiological as much as chemical.

There is no interferon-specific reconstituted-stability figure in the verified literature compiled for this page. Any number circulating informally — "good for X days after mixing" — is either drawn from a specific product's labeling or is an extrapolation from other proteins, and the two should not be conflated.

Shelf Life and Expiry Dating

Expiry dating for a biologic is not a guess about when the molecule becomes unsafe; in regulatory practice it is the period over which the manufacturer has generated real-time and accelerated stability data showing the product remains within specification for potency, purity, particulates and related attributes. Two consequences follow from that definition.

• An expiry date is condition-bound. It applies only to material held under the labeled conditions for its entire history. A product stored outside those conditions has no supported dating, regardless of what the label says.
• Expiry is a specification boundary, not a cliff. General stability science describes potency loss in proteins as gradual and pathway-dependent, which is why stability programmes track assay values over time rather than a single pass/fail day.

Research-grade material sold for laboratory use is a separate category. Research-use-only preparations are not held to the same stability-data requirements as approved drug products, and any stated dating for them typically reflects a supplier's internal handling recommendation rather than a regulatory stability programme.

Room Temperature and Travel

General cold-chain literature distinguishes between a controlled room temperature storage claim (a product formally validated for 20–25 °C storage for a defined period) and a temperature excursion (unplanned time outside the labeled range). Most protein biologics carry no controlled-room-temperature claim at all, which is why excursion policy — how long, how warm, and whether the product is still within specification afterwards — is set by the manufacturer on a product-by-product basis rather than by any universal rule.

The variables that the general literature identifies as relevant during transport are cumulative time above the labeled range, peak temperature reached, mechanical agitation, and freezing events at the cold end. Insulated transport with a validated temperature indicator is the standard approach described for shipping biologics, and airline cabin carriage of temperature-sensitive medicines is addressed by airport security and airline policy rather than by stability science. None of the verified interferon papers on this page examined transport conditions.

Freezing and Freeze–Thaw

Freezing is where the intuition "colder is safer" most often fails for proteins. General protein-formulation science describes several freezing-associated stresses: ice-crystal formation concentrating solutes in the remaining liquid phase, pH shifts as buffer components crystallise out at different rates, and cold denaturation with subsequent aggregation on thaw. Repeated freeze–thaw cycles compound these effects, which is why aliquoting is a standard laboratory practice for frozen protein stocks and why "do not freeze" appears on the labeling of many refrigerated biologics.

Importantly, a lyophilized cake and a solution behave differently here. The general literature treats freezing of an aqueous protein solution as a recognised stress; a properly dried cake has far less free water and is discussed differently. Laboratory reagent-grade cytokine preparations are commonly stored frozen at −20 °C or −80 °C as lyophilized powder or as buffered aliquots, while finished pharmaceutical presentations are typically refrigerated and explicitly not frozen. Those are two different product categories with two different storage rationales, and conflating them is a common error.

Signs of Degradation

General protein-formulation science describes a small set of observable signals and a much larger set of signals that are invisible without instrumentation.

The last row is the one that matters most conceptually: a protein solution can lose a substantial fraction of its biological activity while remaining perfectly clear. Biological activity of interferon is measured in cell-based systems, and functional readouts in that literature are sensitive to the intact signalling protein — for example, one study reported that interferon restored replication fork stability and cell viability in BRCA-defective cells through ISG15 (PMID 37783689). Those are assays of biological function in cell systems, not shelf-life tests, but they illustrate why potency is defined functionally rather than by appearance.

Why Interferon's Biology Is Not a Storage Argument: What Studies Report

Some readers encounter interferon papers describing rapid intracellular clearance of signalling components and assume the molecule is therefore fragile in a vial. The two questions are unrelated. Researchers described STING signalling being terminated through ESCRT-dependent microautophagy of vesicles originating from recycling endosomes (PMID 36918692), and a separate report described ISGylation by HERC enzymes facilitating STING activation (PMID 38652662) — both describe regulated cellular processes with dedicated enzymatic machinery, not spontaneous chemical decay.

The same holds for interferon's antiviral effects. The study published in Science in 2014 described specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA (PMID 24557838), and a later report described p-STAT3-elevated DTX4 conferring stability of HBV cccDNA by ubiquitinating APOBEC3B in liver (PMID 39346550). Researchers also reported that blocking IFN-P-body-XRN1 axis-mediated degradation enhanced mRNA therapeutics (PMID 41997928). Collectively these reports concern enzyme-mediated turnover of nucleic acids and proteins in cells (PMID 24557838), not the thermal or mechanical stability of a formulated product.

What the Available Evidence Does Not Establish

• No interferon-specific vial stability figures appear in the verified literature compiled here. Statements about hours, days or months of stability under any condition would have to come from product labeling or from dedicated stability studies not represented in this citation set.
• General protein science does not transfer cleanly between formulations. Two interferon products with different excipients, pH, preservative status and container systems can have materially different stability profiles.
• Appearance is an incomplete test. Visual inspection detects only the coarse end of a degradation spectrum, as the general formulation literature repeatedly emphasises.
• Research-use-only material carries no stability guarantee comparable to an approved product's dating, because it is not produced under the same regulatory stability framework.

References

• ISGylation by HERCs facilitates STING activation (Cell Reports, 2024)
• Interferon restores replication fork stability and cell viability in BRCA-defective cells via ISG15 (Nature Communications, 2023)
• Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA (Science, 2014)
• p-STAT3-elevated E3 ubiquitin ligase DTX4 confers the stability of HBV cccDNA by ubiquitinating APOBEC3B in liver (Theranostics, 2024)
• STING signalling is terminated through ESCRT-dependent microautophagy of vesicles originating from recycling endosomes (Nature Cell Biology, 2023)
• E3 ubiquitin ligase Stub1 enhances viral replication by promoting TBK1 degradation through molecular chaperone-mediated autophagy (Cell Death and Differentiation, 2026)
• MARCH8-mediated ubiquitination regulates expression of the antiviral protein IFITM3 (Journal of Biological Chemistry, 2025)
• Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation (Nature Communications, 2026)
• The CRL5-SPSB3 ubiquitin ligase targets nuclear cGAS for degradation (Nature, 2024)